FeesSafety
Pluang+

Firmonertinib shows promise as first oral targeted therapy for EGFR PACC-mutant NSCLC in Phase 1b results

Market News
19 Oct 2026, 15:01 WIB
GlobeNewsWire
View Source
Bullish
Firmonertinib shows promise as first oral targeted therapy for EGFR PACC-mutant NSCLC in Phase 1b results

ArriVent BioPharma published Phase 1b results for firmonertinib, highlighting its potential as the first oral, chemotherapy-free targeted therapy for treatment-naïve patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC). This mutation affects about 12% of EGFR-mutant lung cancers and currently lacks a standard targeted treatment. The drug demonstrated strong clinical activity, including high response rates and progression-free survival, as well as meaningful brain metastasis response. ArriVent is advancing firmonertinib into a global Phase 3 trial to address this significant unmet medical need.

ArriVent's cancer cell publication on firmonertinib comes as the health sector on Pluang shows mixed activity, with 68 of 150 priced US health stocks rising and 54 falling as of Oct 19, 2026, 18:43 WIB. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.37 with a 2.49% increase, Revolution Medicines Inc. (RVMD) at USD 181.96 up 2.25%, and Arrowhead Pharmaceuticals Inc. (ARWR) at USD 56.94 rising 1.86%. Typical hold times on Pluang vary from 4 to 36 days among these stocks.

More News

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
46 minutes ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
1 hour ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
2 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
2 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 in early November 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 in early November 2026

Rexel Développement SAS announced it bought back a total of 3,878 of its own shares between November 9 and 13, 2026, at an average price of €34.67 per share. This share repurchase is part of the authorization granted by its shareholders to operate on...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App